Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 24 August 1990:
Vol. 249. no. 4971, pp. 932 - 935
DOI: 10.1126/science.2392685
Prev | Table of Contents | Next

Articles

Science, Vol 249, Issue 4971, 932-935
Copyright © 1990 by American Association for the Advancement of Science

articles

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant

GJ LaRosa, JP Davide, K Weinhold, JA Waterbury, AT Profy, JA Lewis, AJ Langlois, GR Dreesman, RN Boswell, P Shadduck, and al. et

Repligen Corporation, Cambridge, MA 02139.

The principal neutralizing determinant (PND) of human immunodeficiency virus HIV-1 is part of a disulfide bridged loop in the third variable region of the external envelope protein, gp120. Analysis of the amino acid sequences of this domain from 245 different HIV-1 isolates revealed that the PND is less variable than thought originally. Conservation to better than 80 percent of the amino acids in 9 out of 14 positions in the central portion of the PND and the occurrence of particular oligopeptide sequences in a majority of the isolates suggest that there are constraints on PND variability. One constraining influence may be the structural motif (beta strand--type II beta turn--beta strand--alpha helix) predicted for the consensus PND sequence by a neural network approach. Isolates with a PND similar to the commonly investigated human T cell lymphoma virus IIIB (HTLV-IIIB) and LAV-1 (BRU) strains were rare, and only 14 percent of sera from 86 randomly selected HIV-1 seropositive donors contained antibodies that recognized the PND of these virus isolates. In contrast, over 65 percent of these sera reacted with peptides containing more common PND sequences. These results suggest that HIV vaccine immunogens chosen because of their similarity to the consensus PND sequence and structure are likely to induce antibodies that neutralize a majority of HIV-1 isolates.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response.
M. E. Laird, T. Igarashi, M. A. Martin, and R. C. Desrosiers (2008)
J. Virol. 82, 11054-11065
   Abstract »    Full Text »    PDF »
Mapping of the CXCR4 Binding Site within Variable Region 3 of the Feline Immunodeficiency Virus Surface Glycoprotein.
M. Sundstrom, R. L. White, A. de Parseval, K. J. Sastry, G. Morris, C. K. Grant, and J. H. Elder (2008)
J. Virol. 82, 9134-9142
   Abstract »    Full Text »    PDF »
Unique Mutational Patterns in the Envelope {alpha}2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1.
R. Rong, S. Gnanakaran, J. M. Decker, F. Bibollet-Ruche, J. Taylor, J. N. Sfakianos, J. L. Mokili, M. Muldoon, J. Mulenga, S. Allen, et al. (2007)
J. Virol. 81, 5658-5668
   Abstract »    Full Text »    PDF »
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1..
B. Li, J. M. Decker, R. W. Johnson, F. Bibollet-Ruche, X. Wei, J. Mulenga, S. Allen, E. Hunter, B. H. Hahn, G. M. Shaw, et al. (2006)
J. Virol. 80, 5211-5218
   Abstract »    Full Text »    PDF »
Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif..
Y. Eda, M. Takizawa, T. Murakami, H. Maeda, K. Kimachi, H. Yonemura, S. Koyanagi, K. Shiosaki, H. Higuchi, K. Makizumi, et al. (2006)
J. Virol. 80, 5552-5562
   Abstract »    Full Text »    PDF »
Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection..
Y. Eda, T. Murakami, Y. Ami, T. Nakasone, M. Takizawa, K. Someya, M. Kaizu, Y. Izumi, N. Yoshino, S. Matsushita, et al. (2006)
J. Virol. 80, 5563-5570
   Abstract »    Full Text »    PDF »
Fold Recognition of the Human Immunodeficiency Virus Type 1 V3 Loop and Flexibility of Its Crown Structure During the Course of Adaptation to a Host.
T. Watabe, H. Kishino, Y. Okuhara, and Y. Kitazoe (2006)
Genetics 172, 1385-1396
   Abstract »    Full Text »    PDF »
Compartmentalization of Human Immunodeficiency Virus Type 1 between Blood Monocytes and CD4+ T Cells during Infection.
J. A. Fulcher, Y. Hwangbo, R. Zioni, D. Nickle, X. Lin, L. Heath, J. I. Mullins, L. Corey, and T. Zhu (2004)
J. Virol. 78, 7883-7893
   Abstract »    Full Text »    PDF »
N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies.
R. A. McCaffrey, C. Saunders, M. Hensel, and L. Stamatatos (2004)
J. Virol. 78, 3279-3295
   Abstract »    Full Text »    PDF »
Compartmentalization of Surface Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 during Acute and Chronic Infection.
L. Zhang, L. Rowe, T. He, C. Chung, J. Yu, W. Yu, A. Talal, M. Markowitz, and D. D. Ho (2002)
J. Virol. 76, 9465-9473
   Abstract »    Full Text »    PDF »
Selection following isolation of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and herpesvirus saimiri-transformed T cells is comparable.
N. N. Zheng, C. Vella, P. J. Easterbrook, and R. S. Daniels (2002)
J. Gen. Virol. 83, 1343-1352
   Abstract »    Full Text »    PDF »
Neutralization Profiles of Sera from Human Immunodeficiency Virus (HIV)-Infected Individuals: Relationship to HIV Viral Load and CD4 Cell Count.
M. Nokta, P. Turk, K. Loesch, and R. B. Pollard (2000)
Clin. Vaccine Immunol. 7, 412-416
   Abstract »    Full Text »    PDF »
CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.
W.-K. Wang, T. Dudek, Y.-J. Zhao, H. G. Brumblay, M. Essex, and T.-H. Lee (1998)
PNAS 95, 5740-5745
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia.
A. Ghorpade, A. Nukuna, M. Che, S. Haggerty, Y. Persidsky, E. Carter, L. Carhart, L. Shafer, and H. E. Gendelman (1998)
J. Virol. 72, 3340-3350
   Abstract »    Full Text »    PDF »
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines.
R. I. Connor, B. T. M. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, et al. (1998)
J. Virol. 72, 1552-1576
   Abstract »    Full Text »    PDF »
Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 (HIV-1) V3 Loop Chimeras from a Combinatorial Library Induce Potent Neutralizing Antibody Responses against HIV-1.
A. D. Smith, S. C. Geisler, A. A. Chen, D. A. Resnick, B. M. Roy, P. J. Lewi, E. Arnold, and G. F. Arnold (1998)
J. Virol. 72, 651-659
   Abstract »    Full Text »    PDF »
Extent of Antigenic Diversity in the V3 Region of the Surface Glycoprotein, gp120, of Human Immunodeficiency Virus Type 1 Group M and Consequences for Serotyping.
J.-C. Plantier, S. Le Pogam, F. Poisson, L. Buzelay, B. Lejeune, and F. Barin (1998)
J. Virol. 72, 677-683
   Abstract »    Full Text »    PDF »
Synthetic Soluble Analogs of Galactosylceramide (GalCer) Bind to the V3 Domain of HIV-1 gp120 and Inhibit HIV-1-induced Fusion and Entry.
J. Fantini, D. Hammache, O. Delezay, N. Yahi, C. Andre-Barres, I. Rico-Lattes, and A. Lattes (1997)
J. Biol. Chem. 272, 7245-7252
   Abstract »    Full Text »    PDF »
Contribution of Arginine Residues in the RP135 Peptide Derived from the V3 Loop of gp120 to Its Interaction with the Fv Fragment of the 0.5beta HIV-1 Neutralizing Antibody.
G. A. Faiman, R. Levy, J. Anglister, and A. Horovitz (1996)
J. Biol. Chem. 271, 13829-13833
   Abstract »    Full Text »    PDF »
Structure and Polymorphism of HIV-1 Third Variable Loops.
P. Catasti, E. M. Bradbury, and G. Gupta (1996)
J. Biol. Chem. 271, 8236-8242
   Abstract »    Full Text »    PDF »
Candidate AIDS Vaccines.
B. S. Graham and P. F. Wright (1995)
N. Engl. J. Med. 333, 1331-1339
   Full Text »    PDF »
Local and Global Structural Properties of the HIV-MN V3 Loop.
P. Catasti, J. D. Fontenot, E. M. Bradbury, and G. Gupta (1995)
J. Biol. Chem. 270, 2224-2232
   Abstract »    Full Text »    PDF »
Crystal structure of the principal neutralization site of HIV-1.
J. Ghiara, E. Stura, R. Stanfield, A. Profy, and I. Wilson (1994)
Science 264, 82-85
   Abstract »    PDF »
T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells.
C Callebaut, B Krust, E Jacotot, and A. Hovanessian (1993)
Science 262, 2045-2050
   Abstract »    PDF »
Vaccines against Human Immunodeficiency Virus -- Progress and Prospects.
N. L. Letvin (1993)
N. Engl. J. Med. 329, 1400-1405
   Full Text »
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
S. Hwang, T. Boyle, H. Lyerly, and B. Cullen (1992)
Science 257, 535-537
   Abstract »    PDF »
Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.
H Takahashi, Y Nakagawa, C. Pendleton, R. Houghten, K Yokomuro, R. Germain, and J. Berzofsky (1992)
Science 255, 333-336
   Abstract »    PDF »
Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.
C. Wang, D. Looney, M. Li, A. Walfield, J Ye, B Hosein, J. Tam, and F Wong-Staal (1991)
Science 254, 285-288
   Abstract »    PDF »
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
K. Steimer, C. Scandella, P. Skiles, and N. Haigwood (1991)
Science 254, 105-108
   Abstract »    PDF »
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications.
G. LaRosa, K Weinhold, A. Profy, A. Langlois, G. Dreesman, R. Boswell, P Shadduck, D. Bolognesi, T. Matthews, E. Emini, et al. (1991)
Science 253, 1146
   PDF »
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
S. Hwang, T. Boyle, H. Lyerly, and B. Cullen (1991)
Science 253, 71-74
   Abstract »    PDF »
LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur.
S Wain-Hobson, J. Vartanian, M Henry, N Chenciner, R Cheynier, S Delassus, L. Martins, M Sala, M. Nugeyre, D Guetard, et al. (1991)
Science 252, 961-965
   Abstract »    PDF »
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: corrections and clarifications.
G. LaRosa, J. Davide, K Weinhold, J. Waterbury, A. Profy, J. Lewis, A. Langlois, G. Dreesman, R. Boswell, P Shadduck, et al. (1991)
Science 251, 811
   PDF »
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
K Javaherian, A. Langlois, G. LaRosa, A. Profy, D. Bolognesi, W. Herlihy, S. Putney, and T. Matthews (1990)
Science 250, 1590-1593
   Abstract »    PDF »
The Binding of a Glycoprotein 120 V3 Loop Peptide to HIV-1 Neutralizing Antibodies. STRUCTURAL IMPLICATIONS.
G. Wu, R. MacKenzie, P. J. Durda, and P. Tsang (2000)
J. Biol. Chem. 275, 36645-36652
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)